Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 3
---
 under the Securities Act, there are also being registered such securities that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions. No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the 2024 Resale Registration Statements, as applicable.

The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>bioAffinity Technologies, Inc.

2,851,586Shares of Common Stock</div>

This prospectus relates to the resale from time to time of up to 2,851,586 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc., consisting of 2,591,586 shares of Common Stock issuable upon the exercise of warrants and 260,000 shares of Common Stock previously issued upon the exercise of warrants, as set forth below:

| ● | the                                                                                              
 resale of up to 565,333 shares of Common Stock that are issuable upon exercise of outstanding    
 warrants issued in connection with our March 2024 private placement, the resale of such shares   
 of Common Stock were previously registered on Registration Statement No. 333-278512;             |
| ● | the                                                                                              
 resale of up to 499,862 shares of Common Stock that are issuable upon exercise of outstanding    
 warrants issued in connection with our August 2024 private placement, the resale of such         
 shares of Common Stock were previously registered on Registration Statement No. 333-282045;      |
| ● | the                                                                                              
 resale of up to 1,526,391 shares of Common Stock that are issuable upon exercise of outstanding  
 warrants issued in connection with our October 2024 private placement and up to 260,000 shares   
 of Common Stock that were issued upon the exercise of warrants issued in the October 2024        
 private placement and that continue to be held by certain of the selling stockholders identified 
 in, the issuance of which were previously registered on Registration Statement No. 333-283521.   |

On April 4, 2024, we filed a Registration Statement